US FDA declines to approve Disc Medicine’s rare disease drug

Reuters | February 13, 2026

A clear overview of the CRL, including that bitopertin had been reviewed under the FDA’s Commissioner’s National Priority Voucher program and that the agency did not find enough evidence linking the biomarker response to clinical benefit.